Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Patients with coexisting conditions or who have poor outcomes with standard therapy—a large majority of which are older adults—struggle with standard treatments for chronic and small lymphocytic ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed. According ...

We report herein a case of thyroid mucosa-associated lymphoid tissue (MALT) lymphoma in a patient ... infiltration of small- to medium-sized atypical lymphoid cells. 67 Ga scintigraphy was ...

Where did all the cute little smartphones go? Remember "big" 5-inch phones when they first came out? People thought they were huge! The screen size started to crawl up slowly but surely, and nowadays ...

H.C. Wainwright adjusted their valuation of Nurix shares, increasing the price target from $35.00 to $36.00, while reaffirming a Buy rating on the stock. According to InvestingPro data, analysts ...